298 related articles for article (PubMed ID: 30977414)
1. Getting personal with myelodysplastic syndromes: is now the right time?
Chokr N; Pine AB; Bewersdorf JP; Shallis RM; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Apr; 12(4):215-224. PubMed ID: 30977414
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes.
Kobbe G; Schroeder T; Rautenberg C; Kaivers J; Gattermann N; Haas R; Germing U
Expert Rev Hematol; 2019 Oct; 12(10):821-831. PubMed ID: 31322458
[No Abstract] [Full Text] [Related]
3. Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome.
Kawata E; Lazo-Langner A; Xenocostas A; Hsia CC; Howson-Jan K; Deotare U; Saini L; Yang P; Broadbent R; Levy M; Howlett C; Stuart A; Kerkhof J; Santos S; Lin H; Sadikovic B; Chin-Yee I
Br J Haematol; 2021 Feb; 192(4):729-736. PubMed ID: 32588428
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
Shapiro RM; Kim DDH
Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
[TBL] [Abstract][Full Text] [Related]
5. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
6. Mutational profiling in patients with MDS: ready for every-day use in the clinic?
Bacher U; Kohlmann A; Haferlach T
Best Pract Res Clin Haematol; 2015 Mar; 28(1):32-42. PubMed ID: 25659728
[TBL] [Abstract][Full Text] [Related]
7. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
Hughes CFM; Gallipoli P; Agarwal R
Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
[TBL] [Abstract][Full Text] [Related]
8. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.
Bacher U; Shumilov E; Flach J; Porret N; Joncourt R; Wiedemann G; Fiedler M; Novak U; Amstutz U; Pabst T
Blood Cancer J; 2018 Nov; 8(11):113. PubMed ID: 30420667
[TBL] [Abstract][Full Text] [Related]
9. The evolving role of next generation sequencing in myelodysplastic syndromes.
Spaulding TP; Stockton SS; Savona MR
Br J Haematol; 2020 Jan; 188(2):224-239. PubMed ID: 31571207
[TBL] [Abstract][Full Text] [Related]
10. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
11. Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants Associated with Myelodysplastic Syndrome in Myeloid Malignancies.
Jiang L; Pallavajjala A; Huang J; Haley L; Morsberger L; Stinnett V; Hardy M; Park R; Ament C; Finch A; Shane A; Parish R; Nozari A; Long P; Adams E; Smith K; Parimi V; Dougaparsad S; Long L; Gocke CD; Zou YS
J Mol Diagn; 2021 Apr; 23(4):467-483. PubMed ID: 33577993
[TBL] [Abstract][Full Text] [Related]
12. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
13. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.
Pine AB; Chokr N; Stahl M; Steensma DP; Sekeres MA; Litzow MR; Luger SM; Stone RM; Greenberg PL; Bejar R; Bewersdorf JP; Gore SD; Zeidan AM
Leuk Lymphoma; 2020 Jun; 61(6):1455-1464. PubMed ID: 32026740
[TBL] [Abstract][Full Text] [Related]
14. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.
Abdulbaki R; Pullarkat ST
Curr Oncol; 2024 Apr; 31(5):2353-2363. PubMed ID: 38785456
[TBL] [Abstract][Full Text] [Related]
15. How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes.
Steensma DP
Blood; 2018 Oct; 132(16):1657-1663. PubMed ID: 30185432
[TBL] [Abstract][Full Text] [Related]
16. The Dawn of next generation DNA sequencing in myelodysplastic syndromes- experience from Pakistan.
Anwar N; Memon FA; Shahid S; Shakeel M; Irfan M; Arshad A; Naz A; Ujjan ID; Shamsi T
BMC Genomics; 2021 Dec; 22(1):903. PubMed ID: 34915860
[TBL] [Abstract][Full Text] [Related]
17. [How Myelodysplastic Syndrome is Diagnosed].
Silzle T
Ther Umsch; 2022; 79(2):77-85. PubMed ID: 35291852
[TBL] [Abstract][Full Text] [Related]
18. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
Wall M
Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
[TBL] [Abstract][Full Text] [Related]
19. Current status and trends in the diagnostics of AML and MDS.
Shumilov E; Flach J; Kohlmann A; Banz Y; Bonadies N; Fiedler M; Pabst T; Bacher U
Blood Rev; 2018 Nov; 32(6):508-519. PubMed ID: 29728319
[TBL] [Abstract][Full Text] [Related]
20. [Molecular Markers of Prognosis in Myelodysplastic Syndromes--Review].
Xu YY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):285-9. PubMed ID: 26913438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]